AdvisorNet Financial Inc Has $2 Million Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

AdvisorNet Financial Inc raised its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 19.8% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 21,960 shares of the company’s stock after acquiring an additional 3,630 shares during the period. AdvisorNet Financial Inc’s holdings in GE HealthCare Technologies were worth $1,996,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. Wynn Capital LLC lifted its holdings in shares of GE HealthCare Technologies by 4.1% in the first quarter. Wynn Capital LLC now owns 3,125 shares of the company’s stock valued at $284,000 after purchasing an additional 122 shares in the last quarter. Fiduciary Trust Co lifted its holdings in GE HealthCare Technologies by 1.8% during the fourth quarter. Fiduciary Trust Co now owns 7,696 shares of the company’s stock worth $595,000 after acquiring an additional 133 shares during the period. Janney Capital Management LLC lifted its holdings in GE HealthCare Technologies by 4.7% during the fourth quarter. Janney Capital Management LLC now owns 3,289 shares of the company’s stock worth $254,000 after acquiring an additional 149 shares during the period. American National Bank lifted its holdings in GE HealthCare Technologies by 25.2% during the fourth quarter. American National Bank now owns 750 shares of the company’s stock worth $58,000 after acquiring an additional 151 shares during the period. Finally, Chilton Capital Management LLC lifted its holdings in GE HealthCare Technologies by 15.4% during the fourth quarter. Chilton Capital Management LLC now owns 1,227 shares of the company’s stock worth $95,000 after acquiring an additional 164 shares during the period. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In related news, CEO Jan Makela sold 20,227 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the completion of the transaction, the chief executive officer now directly owns 63,348 shares in the company, valued at $5,167,296.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other GE HealthCare Technologies news, CEO Jan Makela sold 20,227 shares of GE HealthCare Technologies stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $81.57, for a total transaction of $1,649,916.39. Following the completion of the sale, the chief executive officer now owns 63,348 shares of the company’s stock, valued at $5,167,296.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Frank R. Jimenez purchased 1,315 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were purchased at an average cost of $76.52 per share, with a total value of $100,623.80. Following the purchase, the insider now owns 75,796 shares of the company’s stock, valued at $5,799,909.92. The disclosure for this purchase can be found here. Insiders sold a total of 90,482 shares of company stock worth $7,369,137 over the last ninety days. 0.27% of the stock is owned by corporate insiders.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC opened at $78.85 on Tuesday. The stock has a market cap of $35.99 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 2.85 and a beta of 1.22. GE HealthCare Technologies Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $94.50. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06. The stock has a fifty day moving average of $80.39 and a 200-day moving average of $81.66.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, hitting the consensus estimate of $0.90. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The business had revenue of $4.65 billion during the quarter, compared to analysts’ expectations of $4.80 billion. During the same period in the previous year, the business earned $0.85 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. Equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Argus lifted their price target on GE HealthCare Technologies from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Mizuho dropped their price target on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. The Goldman Sachs Group began coverage on GE HealthCare Technologies in a research note on Thursday, May 30th. They issued a “neutral” rating and a $87.00 target price on the stock. Evercore ISI boosted their target price on GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Finally, Citigroup boosted their target price on GE HealthCare Technologies from $88.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.09.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.